MAZ and breast carcinoma: Our findings show that inhibition of endogenous SAF-1 activity by miR-125b action results in the significant inhibition of VEGF promoter function in the breast cancer cells (Figure 4) where the SAF-1 activity is much higher compared to normal cells [9].